A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 3, 2013, Pages 637-642

  Chao, Yee ^a,b   Wu, Chen Yi ^b,c   Wang, Jack P ^a,b,c   Lee, Rheun Chuan ^a,b   Lee, Wei Ping ^a,b   Li, Chung Pin ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Cisplatin; Gemcitabine; Pancreatic cancer

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883490333     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2239-1     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J et al (2010) (2010) Cancer statistics. CA Cancer J Clin 60(5):277-300
2. American Cancer Society. Survival rates for pancreatic cancer. http://www.cancer.org/Cancer/PancreaticCancer/OverviewGuide/pancreatic-cancer- overview-survival-rates
3. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403-2413
4. Storniolo AM, Enas NH, Brown CA et al (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3,000 patients with pancreatic carcinoma. Cancer 85(6):1261-1268
5. Eastman A (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34(2):155-166
6. Plunkett W, Huang P, Searcy CE et al (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23(5 Suppl 10):3-15
7. Peters GJ, Ruiz van Haperen VW, Bergman AM et al (1996) Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 23(5 Suppl 10):16-24
8. Greene FL, Page DL, Fleming ID et al (2002) Exocrine pancreas. In: AJCC cancer staging manual, 6th edn. Springer, New York, pp 157-164
9. Li CP, Chao Y, Chi KH et al (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57(1):98-104
10. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92(3):205-216
11. Trotti A, Byhardt R, Stetz J et al (2000) Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47(1):13-47
12. Carmichael J, Fink U, Russell RC et al (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73(1):101-105
13. Casper ES, Green MR, Kelsen DP et al (1994) Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12(1):29-34
14. Braakhuis BJ, van Ruiz Haperen VW, Welters MJ (1995) Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31A(13-14):2335-2340
15. Heinemann V, Wilke H, Mergenthaler HG et al (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11(11):1399-1403
16. Philip PA, Zalupski MM, Vaitkevicius VK et al (2001) Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92(3):569-577
17. Brodowicz T, Wolfram RM, Kostler WJ et al (2000) Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 11(8):623-628
18. Colucci G, Giuliani F, Gebbia V et al (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94(4):902-910
19. Heinemann V, Quietzsch D, Gieseler F et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24(24):3946-3952
20. Cascinu S, Labianca R, Catalano V et al (2003) Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian group for the study of digestive tract cancer (GISCAD). Ann Oncol 14(2):205-208
21. Hu J, Zhao G, Wang HX et al (2011) A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 4(1):11
22. de Xie R, Liang HL, Wang Y et al (2006) Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone. Chin J Dig Dis 7(1):49-54
23. Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25(18):2607-2615
24. Park JK, Yoon YB, Kim YT et al (2008) Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol 42(1):86-91